A number of investment brokers have recently updated their price targets on shares of Arbutus Biopharma Corporation (ABUS). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

11/06/2015 – Arbutus Biopharma Corporation had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 20 price target on the stock.

10/29/2015 – Arbutus Biopharma Corporation had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 12 price target on the stock.

09/02/2015 – JMP Securities began new coverage on Arbutus Biopharma Corporation giving the company a “market outperform” rating. They now have a USD 13 price target on the stock.

08/07/2015 – Wedbush began new coverage on Arbutus Biopharma Corporation giving the company a “outperform” rating. They now have a USD 20 price target on the stock.

The share price of Arbutus Biopharma Corporation (ABUS) was down -7.98% during the last day of trading, with a day high of 4.57. 133884 shares were traded during the last session.

The stock’s 50 day moving average is 4.63 and its 200 day moving average is 4.46. The stock’s market capitalization is 226.46M. Arbutus Biopharma Corporation has a 52-week low of 2.72 and a 52-week high of 15.63.

View other investors thoughts on Arbutus Biopharma Corporation with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.